Figure 6.

Administration of BiZn did not affect the antitumor effect of cisplatin on adrenal tumors. In (A), 0.2 × 10⁶ SKNLP neuroblastoma cells were injected into mouse adrenal gland for 4 weeks to induce adrenal tumors. Mice with adrenal tumors were divided into four groups: control, BiZn-treated, cisplatin-treated, and BiZn combined with cisplatin–treated groups. Live cell imaging luciferrin scan was used to evaluate the antitumor activity weekly. Three-week cisplatin- and cisplatin plus BiZn–treated tumors had significantly lower total flux when compared to control tumors (cisplatin-treated and BiZn combined with cisplatin–treated vs. control group, **P < .01). Cisplatin- and cisplatin plus BiZn–treated tumors had no significant difference of total flux. In (B), photos of the tumor after treatment were shown. There is a significant inhibition of tumor growth after 3 weeks cisplatin and cisplatin plus BiZn treatment (cisplatin-treated and BiZn combined with cisplatin–treated vs. control group, *P < .05), and there is no significant difference in tumor volume of cisplatin-treated vs. BiZn combined with cisplatin–treated group.